Ultragenyx price target lowered to $115 from $140 at Piper Sandler
Piper Sandler lowered the firm’s price target on Ultragenyx (RARE) to $115 from $140 and keeps an Overweight rating on the shares after analyst ...
Ultragenyx Pharmaceutical (RARE) Gets a Buy from Piper Sandler
Piper Sandler analyst Allison Bratzel maintained a Buy rating on Ultragenyx Pharmaceutical (RARE – Research Report) today and set a price ...
Nasdaq22d
Ultragenyx to Participate at Investor Conferences in March
Monday, March 3, 2025, Eric Crombez, M.D., Chief Medical Officer, will participate in a fireside chat and host 1x1 meetings. Wednesday, March 12, 2025, Eric Crombez will participate in a fireside ...